Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Clinical trial NCT05920863 · RECRUITING

Trial details

NCT number: NCT05920863
Sponsor: Zhejiang Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Lenvatinib Tislelizumab TACE Pharmorubicin Oxaliplatin

Start date: 2023-07-01
Primary completion: 2025-12-31
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.